Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance and pharmacokinetics study of oral [14C]BTZ-043 in healthy male volunteers
NL-OMON50849Completed
- Sponsor
- LMU Klinikum
- Start
- Sep 2021
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of BTZ-043 in Tuberculosis (TB), sponsored by LMU Klinikum. Primary endpoint: Excretion routes and mass balance of [14C]BTZ-043-related radioactivity. Started Sep 2021; status: completed.
02
Drugs
BTZ-043
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NL-OMON50849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50849.